Nitrogen mustard in severe rheumatoid arthritis

Area of Science:

• Rheumatology
• Oncology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease causing joint inflammation and damage.
• Severe active RA requires effective therapeutic interventions to manage disease activity and prevent long-term disability.
• Intravenous chemotherapy agents have been explored for their immunomodulatory effects in autoimmune conditions.

Purpose of the Study:

• To evaluate the efficacy and safety of intravenous bolus nitrogen mustard therapy in patients with severe active rheumatoid arthritis.
• To assess the short-term and long-term effects of this treatment on clinical and laboratory parameters of RA disease activity.

Main Methods:

• A controlled study involving 11 patients with severe active RA, with 7 receiving nitrogen mustard and 4 serving as controls.
• Prospective evaluation of 22 patients treated with intravenous bolus nitrogen mustard over a 6-18 month period.
• Dosage regimen: 3 intravenous bolus injections of 0.1 mg/kg body weight over 3-5 weeks.

Main Results:

• Actively treated patients exhibited greater improvement in all measured clinical and laboratory variables compared to controls.
• The treatment demonstrated a persistent effect over 6-18 months.
• Clinically significant improvements in disease activity assessments were observed.

Conclusions:

• Intravenous bolus nitrogen mustard therapy is valuable for severe active rheumatoid arthritis.
• Treatment should be reserved for hospitalized patients with severe RA.
• Combination therapy, including nitrogen mustard, may enhance treatment outcomes.